Mafalda Ramos

6PUBLICATIONS
8CO-AUTHORS
Pharmaceutical delivery technologiesDental materials and equipmentEconometric and statistical methodsEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 15, 2025
The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.

Mafalda Ramos, Sara Larsen, Francesco Fusco

|Nov 29, 2021
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.

Lars H Ehlers, Mark Lamotte, Mafalda C Ramos

|Aug 05, 2021
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.

Mafalda Ramos, Peng Men, Xu Wang

|Feb 12, 2021
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.

Ahmed Salem, Peng Men, Mafalda Ramos

|Jun 24, 2020
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.

Mafalda Ramos, Anastasia Ustyugova, Nikco Hau

|Oct 12, 2019
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.

Mafalda Ramos, Volker Foos, Anastasia Ustyugova

Pageof 1

Frequent Collaborators

1 joint publications

Lars H Ehlers

1 joint publications

Susanne Sandgaard

1 joint publications

Pia Holmgaard

1 joint publications

Evan C Frary